Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601900 · ClinicalTrials.gov registry record · Phase 3
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 394
- Enrollment target
NCT00601900: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00601900 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 394 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00601900, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 394 participants
- Enrollment target
Study Summary
This randomized phase III trial studies tamoxifen citrate or letrozole together with bevacizumab to see how well it works compared with tamoxifen citrate or letrozole alone in treating women with stage IIIB or stage IV breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving hormone therapy is more effective with or without bevacizumab in treating advanced breast cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG Letrozole
- BIOLOGICAL Bevacizumab
- DRUG Tamoxifen Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2008-09-24 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601900
The ClinicalTrials.gov registry entry for NCT00601900 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 394 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00601900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00601900 about?
NCT00601900 is a clinical study titled "Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer". This randomized phase III trial studies tamoxifen citrate or letrozole together with bevacizumab to see how well it works compared with tamoxifen citrate or letrozole alone in treating women with stage IIIB or stage IV breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone ther...
What is the current status of trial NCT00601900?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 394 participants. The study started on 2008-09-24. Estimated completion is 2025-05-01.
What interventions are being tested in trial NCT00601900?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Letrozole (DRUG), Bevacizumab (BIOLOGICAL), Tamoxifen Citrate (DRUG).
Who is sponsoring clinical trial NCT00601900?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.